Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
2,466
Views
0
CrossRef citations to date
0
Altmetric
Report

Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance

M. Frank Erasmusa Specifica, LLC, a Q Solutions Company, Santa Fe, NM, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8046-5048View further author information
ORCID Icon,
Molly Dovnerb Sapidyne, Inc, Boise, ID, USAView further author information
,
Fortunato Ferraraa Specifica, LLC, a Q Solutions Company, Santa Fe, NM, USAView further author information
,
Sara D’Angeloa Specifica, LLC, a Q Solutions Company, Santa Fe, NM, USAView further author information
,
André A. Teixeiraa Specifica, LLC, a Q Solutions Company, Santa Fe, NM, USAView further author information
,
Camila Leal-Lopesa Specifica, LLC, a Q Solutions Company, Santa Fe, NM, USAView further author information
,
Laura Spectora Specifica, LLC, a Q Solutions Company, Santa Fe, NM, USAView further author information
,
Elizabeth Hopkinsb Sapidyne, Inc, Boise, ID, USAView further author information
&
Andrew R. M. Bradburya Specifica, LLC, a Q Solutions Company, Santa Fe, NM, USACorrespondence[email protected]
View further author information
 show all
Article: 2291209 | Received 26 Oct 2023, Accepted 30 Nov 2023, Published online: 13 Dec 2023

References

  • Martin KP, Grimaldi C, Grempler R, Hansel S, Kumar S. Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics. MAbs. 2023;15(1):2191301. doi:10.1080/19420862.2023.2191301.
  • Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–8. doi:10.1080/19420862.2018.1556465.
  • Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114(5):944–949. doi:10.1073/pnas.1616408114.
  • Azevedo Reis Teixeira A, Erasmus MF, D’Angelo S, Naranjo L, Ferrara F, Leal-Lopes C, Durrant O, Galmiche C, Morelli A, Scott-Tucker A, et al. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. MAbs. 2021;13(1):1980942. doi:10.1080/19420862.2021.1980942.
  • Ferrara F, Erasmus MF, D’Angelo S, Leal-Lopes C, Teixeira AA, Choudhary A, Honnen W, Calianese D, Huang D, Peng L, et al. A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. Nat Commun. 2022;13(1):462. doi:10.1038/s41467-021-27799-z.
  • Erasmus MF, Ferrara F, D’Angelo S, Spector L, Leal-Lopes C, Teixeira AA, Sørensen J, Nagpal S, Perea-Schmittle K, Choudhary A, et al. Insights into next generation sequencing guided antibody selection strategies. Sci Rep. 2023;13(1):18370. doi:10.1038/s41598-023-45538-w.
  • Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody–based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol. 2014;193(11):5733–5743. doi:10.4049/jimmunol.1301769.
  • Mao R, Kong W, He Y. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better. Front Immunol. 2022;13:1032403. doi:10.3389/fimmu.2022.1032403.
  • Yu X, Orr CM, Chan HTC, James S, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, Cox KL, Essex JW, et al. Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature. 2023;614(7948):539–547. doi:10.1038/s41586-022-05673-2.
  • Myszka DG. Improving biosensor analysis. J Mol Recognit. 1999;12(5):279–284. doi:10.1002/(SICI)1099-1352(199909/10)12:5<279:AID-JMR473>3.0.CO;2-3.
  • Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, Heine PA, Ballmann R, Schneider K-T, Roth KDR, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12(1):1577. doi:10.1038/s41467-021-21609-2.
  • Knowling S, Clark J, Sjuts H, Abdiche YN. Direct comparison of label-free biosensor binding kinetics obtained on the biacore 8K and the Carterra LSA. SLAS Discov. 2020;25(9):977–984. doi:10.1177/2472555220934814.
  • Brown ME, Bedinger D, Lilov A, Rathanaswami P, Vásquez M, Durand S, Wallace-Moyer I, Zhong L, Nett JH, Burnina I, et al. Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors. PLoS ONE. 2020;15(3):e0229206. doi:10.1371/journal.pone.0229206.
  • Darling RJ, Brault PA. Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev Technol. 2004;2(6):647–657. doi:10.1089/adt.2004.2.647.
  • Bee C, Abdiche YN, Stone DM, Collier S, Lindquist KC, Pinkerton AC, Pons J, Rajpal A. Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions. PLoS ONE. 2012;7(4):e36261. doi:10.1371/journal.pone.0036261.
  • Teixeira AAR, Erasmus MF, D’Angelo S, Naranjo L, Ferrara F, Leal-Lopes C, Durrant O, Galmiche C, Morelli A, Scott-Tucker A, et al. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. MAbs. 2021;13(1):1980942. doi:10.1080/19420862.2021.1980942.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.